hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site

hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site

hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious and respiratory diseases, has announced its latest engagement in a significant Phase 2b field study. The study will assess an influenza drug candidate, marking a milestone as hVIVO’s largest field […]

Mereo BioPharma completes patient enrollment for BPS-804 Phase 2b trial in osteogenesis imperfecta

Mereo BioPharma completes patient enrollment for BPS-804 Phase 2b trial in osteogenesis imperfecta

British specialty biopharma company Mereo BioPharma Group has completed patient enrollment for a Phase 2b clinical trial of its human monoclonal antibody BPS-804, also known as Setrusumab. This trial aims to evaluate BPS-804 as a potential treatment for osteogenesis imperfecta (OI), commonly referred to as brittle bone disease. Osteogenesis imperfecta is a rare genetic disorder […]